ASX-173

• Description:

  ASX-173 is an orally active inhibitor of asparagine synthetase (ASNS) (IC50 = 0.113 μM, Ki = 0.4 nM) . ASX-173 enhances the anticancer activity of L-asparaginase (ASNase) (HY-P1923) . ASX-173 disrupts nucleotide synthesis and induces leukemia cell cycle arrest, apoptosis and autophagy in leukemia cells in combination with ASNase. ASX-173 slows the growth of OCI-AML2 xenografts in combination with ASNase. ASX-173 is indicated for the study of acute lymphoblastic leukemia, acute myeloid leukemia, colorectal cancer, and other cancers[1].

• UNSPSC:

  12352005

• Target:

  Akt; Apoptosis; Atg8/LC3; Autophagy; Caspase; CDK; PARP

• Related Pathways:

  Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; PI3K/Akt/mTOR

• Field of Research:

  Cancer

• Smiles:

  CC[C@@H](C(N1C[C@@H](C2=CC=C(C=C2)F)[C@H](O)[C@@H]1C(NC(C3=CC=CC=C3)C4=CC=CC=C4)=O)=O)N

• Molecular Formula:

  C28H30FN3O3

• Molecular Weight:

  475.55

• References & Citations:

  [1]Victor Tatarskiy , et al. The ASNS inhibitor ASX-173 potentiates L-asparaginase anticancer activity.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  Caspase 3

• CAS Number:

  [2748800-08-8]